Clinical Trial 43671

New Port Richey, FL 34652


Summary:

Ages Eligible for Study:  50 Years to 90 Years

A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Three Dose Strengths of T3D-959 in Subjects with Mild-to-Moderate Alzheimer's Disease.

Once eligibility is confirmed and before the start of the first dose of study drug, subjects will be randomized on a 1:1:1:1 basis to placebo or T3D959 treatment (15mg, 30mg, 45mg) for the 24-week treatment period. Investigators, subjects, and caregivers will be blinded to the treatment assignment.

Study schedule visits: screening, randoization, weeks 4, 8, 16, 24 and 28 (Follow-up visit)



Criteria:
  • Have a reliable caregiver, an identified adult who, in the opinion of the investigator has sufficient contact to knowledgeably report on the subject's daily cognition, function, behavior, safety, compliance and adherence.
  • Have a clinical diagnosis of mild-to-moderate Alzheimer Disease (Stage 4 or 5) according to the NIA-AA (National Institute of Aging - Alzheimer's Association) criteria at screening.

 


Qualified Participants May Receive:

One of the following Intervention/treatment: 

  • Placebo
  • 15mg T3D-959
  • 30mg T3D-959
  • 45mg T3D-959

May include compensation for time and travel 

 

 


Clinical trials are medical research studies designed to test the safety and/or effectiveness of new investigational drugs, devices, or treatments in humans. These studies are conducted worldwide for a range of conditions and illnesses. Learn more about clinical research and participating in a study at About Clinical Trials.